EP0585109

Publication Title:

N-Acetylglucosaminyl transferase, gene coding therefor, corresponding vectors and transformed hosts, processes for production thereof.

Abstract:

Abstract of EP0585109

A beta 1,6-N-acetylglucosaminyl transferase having the following properties: (1) Action: it transfers N-acetylglucosamine from UDP-N-acetylglucosamine to alpha -6-D-mannoside; (2) Substrate specificity: it shows a reactivity of about 79% for GnGnF-bi-PA, about 125% for GnGnGn-tri-PA and about 66% for GnM-Pa, when taking a reactivity for GnGn-bi-PA as 100%; (3) Optimum pH: 6.2 to 6.3; (4) Inhibition, Activation and Stability: Mn<2> <+> is not necessary for expression of activity, and the activity is not inhibited in the presence of 20 mM EDTA; (5) Molecular weight: about 73,000 as determined by SDS-PAGE in the absence of reducing agent; and about 73,000 and about 60,000 as determined in the presence of a reducing agent; (6) Km value: 133 mu M and 3.5 mM for acceptor GnGn-bi-PA and donor UDP-GlcNAc, respectively; and (7) It includes the following peptide fragments: (1) Thr-Pro-Trp-Gly-Lys Asn-Ile-Pro-Ser-Tyr-Val Val-Leu-Asp-Ser-Phe-Gly-Thr-Glu-Pro-Glu-Phe-Asn-His-Ala-Asn-Tyr-Ala (4) Asp-Leu-Gln-Phe-Leu-Leu (5) Asn-Thr-Asp-Phe-Phe-Ile-Gly, and gene coding for said enzyme, and a process for production of the enzyme. Data supplied from the esp@cenet database - Worldwide

Courtesy of http://v3.espacenet.com





(11) Publication number: 0 585 109 A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93306718.3

(51) Int. CI.5: C12N 9/10

(22) Date of filing: 24.08.93

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

- 30 Priority: 24.08.92 JP 245950/92 06.08.93 JP 237118/93
- (43) Date of publication of application : 02.03.94 Bulletin 94/09
- 84 Designated Contracting States:
 AT BE CH DE DK ES FR GB GR IE IT LI LU MC
 NL PT SE
- (1) Applicant: SUNTORY LIMITED 1-40, Dojimahama 2-chome Kita-ku, Osaka-shi, Osaka (JP)
- (71) Applicant: Taniguchi, Naoyuki 201, 2-19-32 Uenohigashi Toyonaka-shi,Osaka (JP)

- (72) Inventor: Taniguchi, Naoyuki
 201, 2-19-32, Uenohigashi
 Toyonaka-shi, Osaka (JP)
 Inventor: Nishikawa, Atsushi
 A5-401, 3-8, Senriminamimachi
 Toyonaka-shi, Osaka (JP)
 Inventor: Yamaguchi, Nozomi, 285-79,
 Shingoryouguchi-cho
 Kuramaguchitori-Teramachi-Nishiiru
 Kita-ku, Kyoto (JP)
- (74) Representative: Stoner, Gerard Patrick et al Mewburn Ellis 2 Cursitor Street London EC4A 1BQ (GB)

- (54) N-Acetylglucosaminyl transferase, gene coding therefor, corresponding vectors and transformed hosts, processes for production thereof.
- (57) A β1,6-N-acetylglucosaminyl transferase having the following properties:
 - Action: it transfers N-acetylglucosamine from UDP-N-acetylglucosamine to α-6-D-mannoside;
 - (2) Substrate specificity: it shows a reactivity of about 79% for GnGnF-bi-PA, about 125% for GnGnGn-tri-PA and about 66% for GnM-Pa, when taking a reactivity for GnGn-bi-PA as 100%;
 - (3) Optimum pH : 6.2 to 6.3;
 - (4) Inhibition, Activation and Stability: Mn²⁺ is not necessary for expression of activity, and the activity is not inhibited in the presence of 20 mM EDTA;
 - (5) Molecular weight: about 73,000 as determined by SDS-PAGE in the absence of reducing agent; and about 73,000 and about 60,000 as determined in the presence of a reducing agent;
 - (6) Km value : 133 μM and 3.5 mM for acceptor GnGn-bi-PA and donor UDP-GlcNAc, respectively ; and
 - (7) It includes the following peptide fragments:
 - (1) Thr-Pro-Trp-Gly-Lys
 - (2) Asn-Ile-Pro-Ser-Tyr-Val
 - (3) Val-Leu-Asp-Ser-Phe-Gly-Thr-Glu-Pro-Glu-Phe-Asn-His-Ala-Asn-Tyr-Ala
 - (4) Asp-Leu-Gin-Phe-Leu-Leu
 - (5) Asn-Thr-Asp-Phe-Phe-Ile-Gly,

and gene coding for said enzyme, and a process for production of the enzyme.

5

10

25

30

40

50

The present invention relates to an enzyme which transfers N-acetylglucosamine from UDP-N-acetylglucosamine to α -6-D-mannoside (UDP-N-Acetylglucosamine: α -6-D-Mannoside β 1-6N-Acetylglucosaminyl transferase; N-Acetylglucosaminyl-transferase; particularly as abbreviated "GnT-V" herein), a gene coding therefor, and a process for production thereof.

Asparagine type sugar chains found in glycoproteins are classified in three types, i.e., high mannose type, complex type and mixed type, on the basis of constituent sugars and the types of branching. Biosynthesis of these Asn type sugar chains starts with transfer of all sugar chain moiety of a lipid intermediate from the lipid intermediate to asparagine of a polypeptide chain during translation thereof in the lumina of the rough-surfaced endoplasmic reticulum.

After that glucose and a portion of mannose are removed in the rough-surfaced endoplasmic reticulum. However, a portion of glycoprotein having Asn type sugar chains located in the rough-surfaced endoplasmic reticulum remains there intact, and they retain with mannose type sugar chain. Other organella glycoproteins, cell surface glycoproteins or secretary glycoproteins are transferred to the Golgi body by Golgi transportation, and mannose is removed. In the Golgi body, Golgi body enzymes, N-acetylglucosaminyl transferases, introduce N-acetylglucosamine and branching structure is formed. By the formation of this branching structure, conversion of high mannose type sugar chain to mixed type sugar chain and complex sugar chain starts, and through the introduction of fucose and then of galactose in the trans Golgi region, and finally, introduction of sialic acid biosynthesis of Asn type sugar chain is completed.

In the steps of the formation of Asn-type sugar chains, it has been found that various enzymes catalyze the reaction. Among them, as enzymes catalyzing the transfer of N-acetylglucosamine, 6 kinds of N-acetylglucosaminyl transferases are known. Schachter et al., Brockausen, I. Caarver, J., and Schachter, H., Biochem. Cell. Biol., 66, 1134 (1988) named the six enzymes which transfer N-acetylglucosamine to the core structure of trimannosyl structure, $Man\alpha I-3(Man\alpha 1-6)$ $Man\beta I-4GlcNAc\beta I-4GlcNAc$ as GnT-1 through GnT-VI.

Among them, the GnT-V is an enzyme participating in the formation of a $\beta(1,6)$ branch structure (-[G-1cNAc- $\beta(1,6)$ Man- $\alpha(1,6)$ Man]-). It is known that the $\beta(1,6)$ branch structure increases in transformed cells and tumorigenic cells (Pierce, M., Arango, J., Tahir, S.H. and Hindsgunl, O., Biochem. Biophs. Res. Commun., 146, 679-684 (1987) and Arango, J. and Pierce, M., J. Cell. Biochem. 257, 13421-13427 (1982)).

Moreover, it was shown that the metastatic ability of tumorigenic cells corelates with the occurrence of $\beta(1,6)$ branch (Hiraizumi, S., Takasaki, S., Shiroki, K., Kochibe, N., and Kobata, H., Arch. Biochem. Biophys. 280, 9-19 (1990)). In biopsies of human breast cancer, reportedly, in 50% of the cases the expression of the $\beta(1,6)$ branch was accelerated (Dennis, J. W., and Laferrte, S. Cancer Res. 49, 945-950 (1989)).

In any case, it is known that the occurrence of $\beta(1,6)$ branch structure is accompanied with an increase of GnT-V activity. As seen from the above, the GnT-V is not only important in that it catalyses formation of the $\beta(1,6)$ branch structure in the biosynthesis of sugar chain, but also important in that it is related to easiness of the metastatic ability and the degree of malignancy of cancer cells.

Among these six N-acetylglucosaminyl transferases, human and rabbit cDNA structures for GnT-I were clarified (Kumar, R., Yang, J., Larsen, R.C., and Stanley, P. Procc. Natl. Acad. Sci. USA, 87, 9948-9952 (1990) and Sarkev, M. Hull, E., Nishikawa, Y., Simpson, R.J., Noritz, R.L., Dunn, R., and Schachter, H., Proc. Natl. Acad. Sci. U.S.A <u>88</u> 234-238 (1991).

On the other hand, the presence of GnT-V was predicted from its enzyme activity, and its purification from various tissues was attempted, but it was very difficult (Nishikawa, A., Gu, J., Fujii, S., and Taniguchi, N. Biochem. Biophys. Acta 103, 313-318 (1990)). However, recently, isolation and purification of GnT-V from rat kidney was reported (Shoreibah, M., G., Handgaul, O., and Picerce, M., J. Biol. Chem. 267, 2920-2927 (1992)).

However, detailed information relating to the gene of said enzyme has not been obtained from rat GnT-V. For human GnT-V, any information including its enzymatic characteristics is not available. Not only GnT-V is very effective for diagnosis as a maker for degree of malignancy of cancer cells, but also it will be useful in that it will make it possible to design metastasis inhibitory agent by establishing a screening system for specific inhibitor. Therefore, it is desired to isolate and purify GnT-V of human origin, and to analyze the structures including the gene and to produce it in a large amount.

Accordingly, in one aspect, the present invention provides GnT-V of human origin. In addition, according to the present invention the gene for the present enzyme isolated, a process enabling large scale production of the enzyme using said gene is developed, and formation of homogeneous sugar chains in the production of a desired product by gene engineering becomes possible.

The present inventors noted a supernatant of cancer cells as a starting material for purification of the present enzyme. However, the present inventors also noted that purification of the enzyme was difficult in the use of a culture supernatant of cancer cells which can grow only in the presence of bovin serum or the like. Accordingly, the present inventors tried to condition various cancer cells for the growth in protein-free medium, and succeeded to establish tens of cancer cells conditioned to some decade protein-free media. Among them,

the present inventor detected an activity of the present enzyme in a culture supernatant from protein-free medium in which QG cells derived from human lung carcinoma (small cell cancer) were cultured, and succeeded to purify the present enzyme.

Accordingly, in one aspect we provide a β 1,6-N-acetylglucosaminyl transferase determined by us as having the following properties:

- (1) Action: it transfers N-acetylglucosamine from UDP-N-acetylglucosamine to α-6-D-mannoside;
- (2) Substrate specificity: it shows a reactivity of about 78% for GnGnF-bi-PA, about 125% for GnGnGntri-PA and about 66% for GnM-PA, when taking a reactivity for GnGn-bi-PA acceptor as 100%;
- (3) Optimum pH: 6.2 to 6.3;

10

15

20

25

40

45

55

- (4) Inhibition, Activation and Stability: Mn²⁺ is not necessary for expression of activity, and the activity is not inhibited in the presence of 20 mM EDTA;
- (5) Molecular weight: about 73,000 as determined by SDS-PAGE in the absence of reducing agent; and about 73,000 and about 60,000 as determined in the presence of a reducing agent;
- (6) Km value: 133 μM and 3.5 mM for acceptor GnGn-bi-PA and donor UDP-GlcNAc, respectively; and
- (7) It includes the following peptide fragments:
 - (1) Thr-Pro-Trp-Gly-Lys
 - (2) Asn-IIe-Pro-Ser-Tyr-Val
 - (3) Val-Leu-Asp-Ser-Phe-Gly-Thr-Glu-Pro-Glu-Phe-Asn-His-Ala-Asn-Tyr-Ala
 - (4) Asp-Leu-Gln-Phe-Leu-Leu
 - (5) Asn-Thr-Asp-Phe-Phe-Ile-Gly

Alternatively stated, the present β 1,6-N-acetylglucosaminyl transferase has an amino acid sequence comprising the amino acid sequence shown in SEQ ID No: 8, or an amino acid sequence wherein one or more than one amino acid residue is modified in the amino acid sequence shown in SEQ ID No: 8. Herein, the amino acid modification means that one or more amino acid residues are added, deleted and/or replaced with other amino acids, but the enzyme activity is available.

The present invention further provides a process for production of the above-mentioned enzyme comprising the steps of culturing QG cells derived from human lung carcinoma, and recovering said enzyme from the culture.

The present invention still further provides a process for production of the above-mentioned enzyme comprising the steps of culturing or raising a host transformed with a DNA coding for said enzyme, and recovering the enzyme from the culture or raised host.

The present invention also relates to gene system encoding the enzyme i.e., DNA, expression vectors and transformed host.

BRIEF EXPLANATION OF THE DRAWINGS

Figure 1 shows an elution profile of Phenyl-Sepharose column chromatography, wherein solid circles linked with solid lines show GnT-V activity. The elution was carried out by decreasing concentration of ammonium sulfate from 40% to 0%. Concentration of ammonium sulfate is shown by a broken line.

Fig. 2 shows an elution profile of hydroxyapatite column chromatography, wherein open circles linked with solid lines show elution profile of protein, and solid circles linked with solid lines show GnT-V activity. In this figure, the arrow shows the starting point of flow of elution buffer. The elution was carried out by forming a concentration gradient from 50 mM to 300 mM phosphate buffer. Concentration of phosphate buffer is shown by a broken line.

Fig. 3 shows an elution profile of UDP-hexanolamine Agarose-column chromatography, wherein open circles linked with solid lines show an elution profile of protein, and solid circles linked with solid lines show GnT-V activity. In the figure, the arrow shows the start point of flow of elution buffer. The elution was carried out by flowing 0.3 M NaCl at a flow rate of 3 ml/hour.

Fig. 4 shows an elution profile of GnGn-Asn Sepharose-column chromatography, wherein open circles linked with solid lines show an elution profile of protein, and solid circles linked with solid lines show GnT-V activity. In the figure, the arrow shows the start point of flow of elution buffer. The elution was carried out by flowing 0.3 M NaCl at a flow rate of 3 ml/hour.

- Fig. 5 shows a result of SDS polyacrylamide gel electrophoresis of the enzyme.
- Fig. 6 shows a result of native polyacrylamide gel electrophoresis of the enzyme.
- Fig. 7 shows a peptide mapping analysis of the enzyme.
- Fig. 8 is a graph showing optimum pH of the enzyme.
- Fig. 9 represents a construction process of an expression vector.
- Fig. 10 is an elution profile of a high performance liquid chromatography showing that the expression prod-

uct, GnT-V, converts a substrate GnGn-bi-PA to a product GnGnGn-tri'-PA.

SPECIFIC EMBODIMENT

5

10

20

25

30

40

45

50

55

QG cells derived from human lung carcinoma cells (small cell cancer) can be cultured by any method conventionally used for culturing animal cells. The QG cells can be cultured by static culture in a protein free medium, that is, the medium is not supplemented with any extrageneous proteins. Note, a culture of the QG cells derived from human lung carcinoma (small cell cancer) was designated as Human lung carcinoma SBM331 and deposited with Fermentation Research Institute Agency of Industrial Science and Technology, 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305, Japan, as FERM BP-3967 on August 18, 1992, under Budapest Treatty.

Enzyme activity can be easily assayed by labeling an acceptor with a radioisotope or with fluorescent substance, adding the enzyme and separating the reaction product by high performance liquid chromatography (HPLC). More specifically, the method reported by Taniguchi et al. (Taniguchi, N., Nishikawa, A., Fujii, S., and Gu. J., Methods Enzymol. 179, 397-408 (1989); Nishikawa, H., Gu, J., Fujii, S., and Taniguchi, N., Biochem. Biophys. Acta, 1035, 313-318 (1990)) may be followed.

Namely, the enzyme activity of GnT-V can be assayed using GnGn-2-aminopyridine (GnGn-bi-PA) as an acceptor, and UDP-GluNAc (Sigma) as a donor. Activity is shown by an amount of transferred N-acetylgluco-samine/hour/mg protein. Note, an amount of protein can be measured according to a reported method (Redinbaugh, M.G., and Turley, R.B., Anal. Biochem. 153, 267-271 (1986)) using a BCA kit (Pierce Chemical Company, Rockford, IL) and using bovine serum albumin as a standard.

The present enzyme may be isolated and purified by using procedures singly or in combination conventionally used for purification of a protein. In addition, as a useful purification method for the present enzyme, an affinity of the enzyme to an acceptor or donor may be used. According to one embodiment of the present invention, a culture supernatant from a protein-free culture is first concentrated by ultrafiltration, and an active fraction is obtained by hydrophobic chromatography using Phenyl-Sepharose.

Next, after absorption to Hydroxylapatite, an active fraction is eluted, and the active fraction is subjected to acceptor column chromatography (UDP-hexanolamine-Agarose) and donor column chromatography (GnGn-Asn-Sepharose), followed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis in the absence of reducing agent to obtain a polypeptide showing a single band.

A particular example for the purification is described in Example 2. As seen from Example 2, the present inventors succeeded to isolate and purify a 20,000-fold purified GnT-V by 4-step purification procedure from the above-mentioned culture supernatant concentrate of protein-free culture, and determined partial amino acid sequences of the enzyme. The enzyme was obtained for the first time by a particular combination of procedures used for isolation and purification of a protein, under particular conditions.

The enzyme having been isolated and purified, and structural properties of the enzyme clarified by us as described hereinafter, the enzyme can be isolated and purified using the known properties as an indicator according to any other combination of conventional procedures used for isolation and purification of a protein. Moreover, synthetic probes can be prepared on the basis of partial amino acid sequences of the present enzyme disclosed herein, genomic library and cDNA library derived from avian, amphibia, mammal and the like can be screened with said probes to isolate genes, and the gene can be used to produce a corresponding enzyme.

An enzyme isolated and purified as described herein has the following properties.

- 1. Action: it transfers N-acetylglucosamine from UDP-N-acetylglucosamine to lpha-6-D-mannoside;
- 2. Substrate specificity: it shows a reactivity of about 78% for GnGnF-bi-PA, about 125% for GmGmGmtri-PA, and about 66% for GnM-PA, when taking a reactivity for GnGn-bi-PA acceptor as 100%;
- 3. Optimum pH for reaction: 6.2 to 6.3;
- 4. Inhibition, Activation and Stability: Mn²⁺ is not necessary for expression of the activity, and the activity is not inhibited in the presence of 20 mM EDTA;
- 5. Molecular weight: as a result obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), it shows a single band corresponding to a molecular weight of about 73,000 under a non-reducing condition, and it shows a band corresponding to a lower molecular weight of about 60,000 in addition to the above-mentioned band of about 73,000. In addition, when the isolated and purified enzyme is subjected to native polyacrylamide gel electrophoresis, the extraction samples from the sections of the native polyacrylamide gel exhibit the enzyme activity in a density dependent manner. From the above result, the isolated and purified protein is confirmed to be the desired GnT-V. A particular result is described in Example 3.

On the other hand, two bands in an SDS-polyacrylamide gel electrophoresis under the reducing con-

dition are excised from the gel, and each fraction is digested with trypsin followed by reverse phase high performance liquid chromatography and peptide mapping. As a result, both the 60 kDa fraction and 73 kDa fractions show similar elution paterns. From this result, it is concluded that both the proteins are derived from the same protein even though there is possibility that one of or both the enzymes have been enzymatically cleaved;

- 6. Km value: 133 μM and 3.5 mM for acceptor GG-bi-PA and donor UDP-GlcNAc, respectively; and
- 7. Peptide fragments: amino acid sequences of peptide fragments obtained by digestion of the enzyme with trypsin were as follows:
 - (1) Thr-Pro-Trp-Gly-Lys

5

10

15

20

25

30

40

55

- (2) Asn-IIe-Pro-Ser-Tyr-Val
- (3) Val-Leu-Asp-Ser-Phe-Gly-Thr-Glu-Pro-Glu-Phe-Asn-His-Ala-Asn-Tyr-Ala
- (4) Asp-Leu-Gln-Phe-Leu-Leu
- (5) Asn-Thr-Asp-Phe-Phe-Ile-Gly

Further a gene coding for the enzyme may be obtained by preparing oligonucleotide probes on the basis of the amino acid sequences of the peptide fragments and screening a genomic library or a cDNA library using the probes.

Gene of the present invention may be cDNA, genomic DNA or chemically synthesized DNA. For example, cDNA can be cloned by polymerase chain reaction (PCR) using nucleotide primers designed on the basis of the partial amino acid sequences, as shown in Example 5, of GnT-V purified from human cells such as QG cells derived from human lung carcinoma. A particular embodiment of the cloning is shown in Example 8.

The invention further provides DNA which codes for a protein having GnT-V activity and which hybridizes with the nucleotide sequence shown in Example 8.

A nucleotide sequence of DNA coding for the present GnT-V and cloned in Example 8, and an amino acid sequence predicted from the nucleotide sequence are shown in SEQ ID No: 8.

Thus, once an amino acid sequence is determined, various modified GnT-V, such as polypeptide wherein one or more amino acids are added to the above-mentioned native amino acid sequence and still maintaining GnT-V activity, a polypeptide wherein one or more amino acids are deleted from the native amino acid sequence and still maintaining GnT-V activity, a polypeptide wherein one or more amino acids are replaced with other amino acids in the native amino acid sequence and still maintaining GnT-V activity, and a polypeptide including any combination of the above-mentioned amino acid addition modification, amino acid deletion modification and amino acid replacement modification, can be designed and produced.

Although the number of amino acids in the above-mentioned amino acid addition, deletion or replacement modification is not limited to the particular number, for example, for the addition modification, the number depends on the purposes of the modification, for example, depends on the number of amino acids of a functional protein used for formation of a hybride protein with the present GnT-V (for example, known proteins for purification or stabilization such as maltose-binding protein, or various biologically active proteins for example cytokines such as IL-3, IL-11), or signal peptide attached to the present protein. For example, the number of added amino acids are 1 to 30, preferably 1 to 10.

For the deletion modification, the number of deleted amino acids is designed and determined so that the modified protein maintains GnT-V activity, and is for example 1 to 30, preferably 1 to 20, or the number of amino acids in regions other than an active region. For the replacement modification, the number of replaced amino acids is designed and determined so that the modified protein maintains GnT-V activity, and is for example 1 to 10, preferably 1 to 5.

Although the nucleotide sequence is shown in SEQ ID No: 8 as a nucleotide sequence coding for GnT-V, gene of the present invention coding for GnT-V is not limited to it. Once an amino acid sequence of native GnT-V or an amino acid sequence of modified GnT-V is determined, various nucleotide sequences coding for the same amino acid sequence by different codons on the basis of the degeneracy of genetic codons can be designed and prepared. In this case, codons used with a high frequency in a host chosen are preferably used.

Although cDNA can be obtained as a gene coding for the native GnT-V of the present invention, as described in Example 8, but not limited thereto. Namely, once a nucleotide sequence coding for an amino acid sequence of the native GnT-V is determined, a gene coding for the native GnT-V can be cloned by a strategy different from the strategy specifically described herein; and also, can be cloned from the genome of cells producing the native GnT-V.

Where a gene is cloned from the genome, various primer nucleotides or probe nucleotides used in Example 8 may be used as probes for screening genomic DNA fragments. Moreover, other probes designed on the basis of the nucleotide sequence shown in SEQ ID No: 8 may be used. General procedure for cloning a desired DNA from genome is well known in the art (Current Protocols in Molecular Biology, John Wiley and Sons, Chapters 5 and 6).

In addition, a gene coding for the native enzyme may be prepared by chemical synthesis. Chemical synthesis of DNA can be easily carried out using an automated DNA synthesizer conventionally used in the art, such as a 396 DNA/RNA synthesizer (Applied Biosystems). Accordingly, a person with ordinary skill in the art can easily synthesize the nucleotide sequence shown in SEQ ID No: 8.

A gene coding for the native enzyme using codons different from native codons can be chemically synthesized as described above, and further can be obtained by a conventional procedure such as site-directed mutagenesis using a DNA or RNA having the nucleotide sequence shown in SEQ ID No: 8 as a template in combination with a mutagenic primer (see, for example, Current Protocols In Molecular Biology, John Wiley & Sons, Chapter 8).

Once a suitable gene coding for the enzyme has been cloned, the gene can be used to produce a recombinant enzyme e.g. according to a conventional gene recombination technique. Namely, a DNA encoding a GnT-V of the present invention is inserted into a suitable vector, and the vector is introduced into an adequate host, and the host is cultured or raised, and the GnT-V is recovered from the culture (cells or medium) or the raised host.

As a host, prokaryote or eukaryote can be used. As prokaryote, bacteria, especially <u>Escherichia coli, Bacillus</u>, such as <u>B. subfilis</u> may be used. As eukaryote, eukaryotic microorganisms, for example, yeast such as the genus <u>saccharomyces</u>, such as <u>S. cerevisiae</u>, insect cells such as cells of <u>Spodoptera frugiperda</u>, cells of <u>Trichoplusia ni</u> or cells of <u>Bombyx mori</u>, animal cells such as human cells, monkey cells, mouse cells can be used. An insect per se., such as Bombyx mori, Trichoplusia ni, or the like can be used.

As expression vectors, plasmid, phage, phagemid, virus (baculovirus for insect, vaccinia virus for animal cells) and the like can be used. A promoter in an expression vector is selected depending on host. For example, as bacterial promoters, for example, lac promoter, trp promoter and the like are used; and as yeast promoters, for example, adhl promoter, pqk promoter and the like are used. As promoters for insect, for example, baculovirus polyhedrin promoter and the like can be used, and promoters for animal cells, for example, early or late promoter for Simian virus 40 and the like may be used.

Transformation of a host with an expression vector can be carried out according to conventional procedures well known in the art, and these procedure are described in Current Protocols in Molecular Biology, John Wiley & Sons. Transformants can be cultured according to conventional procedures.

Purification of GnT-V from a culture can be carried out according to a conventional procedure for isolation and purification of a protein, for example, using ultrafiltration, various column chromatography such as Sepharose chromatography.

EXAMPLES

5

10

15

20

25

30

35

40

50

55

Next, the present invention is further explained by but not limited to the following examples.

Example 1. Culturing of GnT-V producing cells and preparation of culture supernatant

QG cells (FFRM BP-3967) derived from human lung carcinoma (small cell cancer) were cultured in an opticell 5300 (Charles River Inc. Wilmington, MA). 2 x 10⁹ cells were inoculated to a porous ceramic growing chamber (effective surface > 32,000 cm²), and grown to a confluent state using Ham's F-12 medium (Flow) containing 5% bovine serum (GIBCO).

Next, protein-free Ham's F-12 medium containing 10⁻⁸M sodium selenite was continuously added to gradually decrease an amount of serum. After culturing for 2 weeks, 140L of a culture supernatant was obtained. This culture supernatant was concentrated by about 100 folds using an ultrafiltration apparatus equipped with a UF-membrane (Milipore, Bedford, MA). 1.4L of the concentrated supernatant was used as a starting material for purification.

Example 2. Purification of enzyme from the concentrated culture supernatant

(1) Preparation of UDP-hexanolamine agarose and GlcNAc β 1-2Man α 1-3-(GlcNAc β 1-2Man α 1-6) Man β 1-4GlcNAc β 1-4GlcNAc-asparagine (GnGn-Asn) Sepharose

UDP-hexanolamine Agarose was purchased from Sigma (St. Louis, MO). GnGn-Asn was prepared from human transferrin. First, transferrin was digested twice with Pronase (Boehringer Mannheim) in 0.1M borate buffer (pH 8.0) at 37°C for 12 hours, and resulting sugar peptides were separated by a gel filtration column (Toyoperl HW-40, 2.6×100 cm, Tosoh, Tokyo) previously equilibrated with 10 mM acetate buffer (pH 6.0).

Next, the separated sugar peptide was digested with enzymes sialidase (from Arthrobactor ureafa-

<u>cience</u>, available from Nakalai Tesque, Kyoto, Japan) and β-galactosidase (from jack beam, available from Seikagaku Co., Japan) to obtain GnGn-Asn. GnGn-Asn Sepharose was obtained by reacting 100 μmol GnGn-Asn with 10 ml of activated CH-Sepharose (Pharmacia) to linking them.

(2) Phenyl-Sepharose column chromatography 280 ml of Phenyl-Sepharose was filled to a 4.5×18 cm column, and the column was equilibrated with 1.5L of 20 mM potassium phosphate buffer (pH 6.8, ammonium sulfate 40% saturation). 1.3L of the concentrated culture supernatant prepared in Example 1 was saturated with ammonium sulfate to 40% saturation, centrifuged at $3000 \times G$ for 30 minutes, and the resulting supernatant was absorbed to the column.

Elution was carried out by a linear gradient from ammonium sulfate 40% to 0% in 20 mM potassium phosphate buffer (pH 6.8); at a flow rate of 3 ml/min. Absorption at 280 nm and GnT-V enzyme activity were measured. As shown in Fig. 1, the peak of GnT-V was eluted after the peak of absorption at 280 nm. (3) Hydroxyapatite column chromatography

The fractions showing GnT-V enzyme activity eluted from the Phenyl-Sepharose column chromatography were collected, and concentrated with an Amicon YM-30 membrane while simultaneously exchanging the original medium with 20 mM potassium phosphate (pH 6.8). The concentrated fraction was then adsorbed to 55 ml of hydroxyapatite equilibrated with 300 ml of 20 mM potassium phosphate buffer (pH 6.8). Elution was carried out by a linear gradient of 50 mM - 300 mM potassium phosphate buffer (pH 6.8) at a flow rate of 3 ml/min. An elution profile of the hydroxyapatite chromatography is shown in Fig. 2. The peak of GnT-V enzyme activity was eluted separately from most of other proteins.

(4) UDP-hexanolamine Agarose-column chromatography

Next, the fractions from the hydroxyapatite column were collected, and the original medium was exchanged with 10 mM potassium phosphate buffer (pH 6.25) using an Amicon YM-30 membrane. The resulting fraction was adsorbed to 20 ml of UDP-hexanolamine Agarose column previously equilibrated with 100 ml of 10 mM potassium sulfate buffer (pH 6.25). Enzyme was eluted with 10 mM potassium phosphate containing 0.3M NaCl, at a flow rate of 15 ml/min. This elution profile is shown in Fig. 3.

(5) GnGn-Asn Sepharose column chromatography

Finally, GnGn-Asn Sepharose column chromatography was carried out. The active fraction from the UDP-hexanolamine Agarose column was adsorbed to 4 ml of GnGn-Asn Sepharose equilibrated with 20 ml of 10 mM potassium phosphate buffer (pH 6.25) containing 0.3M NaCl, and after washing the column with same buffer, elution was carried out with 30 mM Tris-HCl (pH 9.0) containing 0.3M NaCl at a flow rate of 3 ml/hour. A result is shown in Fig. 4.

Purification yield of the above-mentioned purification process is shown in Table 1. Each step provided more than 70% yield, and final purification ratio was about 20,000.

35

5

10

15

20

25

30

40

45

50

Table 1

Purification steps from culture supernatant of QG cells derived from human lung carcinoma (small cell cancer), cultured in protein-free medium, and corresponding purification yield

Steps	Protein	Specific Activity	Yield	Purifica- tion ratio	
	(mg)	(nmol/h/mg)	8		
Medium ^(a)	3,250	0.4	100	1	
Phenyl- Sepharose	330	2.9	71	7	
Hydroxyapatit	e 110	8.4	67	20	
UDP- hexanolamine- Agarose	12.6	56.7	52	135	
GnGn-Asn- Sepharose	0.06	8323	37	19,800	

⁽a) 1.3L culture supernatant

30 Example 3. SDS polyacrylamide gel electrophoresis and native polyacrylamide gel electrophoresis

SDS polyacrylamide gel electrophoresis was carried out according a reported method (Laemmli, U.K., Nature 227, 680-685, 1970), using 10 - 15% gradient polyacrylamide gel under the reducing condition and non reducing condition. As molecular weight makers, α -lactalbumin (Mmolecular weight 14,400), soybean trypsin inhibitor (M.W. 20,100), carbonic anhydrase (M.W. 30,000), ovalbumin (M.W. 43,000), bovine serum albumin (M.W. 67,000), and phosphorylase b(M.W. 94,000) were used.

A photograph of the gel prepared by staining the present enzyme with Coomassie Brilliant Blue is shown in Fig. 5. In an SDS polyacrylamide gel electrophoresis under the non-reducing condition, a single band having a molecular weight of 73 kDa as determined by comparing with the above-mentioned molecular weight makers was observed. On the other hand in an SDS polyacrylamide gel electrophoresis under the reducing condition, a band of 60 kDa in addition to the band of 73 kDa were observed on the gel. A photograph of a gel of native polyacrylamide gel electrophoresis stained with Coomassie Brilliant Blue and enzyme activity of sections excised from the native polyacrylamide gel electrophoresis are shown in Fig. 6. Levels of the enzyme activity were observed dependent on the densities of the bands. From the above, it was confirmed that the isolated and purified protein is a desired GnT-V.

Example 4. Peptide mapping analysis

5

40

50

55

SDS polyacrylamide gel electrophoresis was carried out under a reducing condition, and bands corresponding to 60 kDa and 73 kDa were excised from the gel. To the sliced gel pieces was added 30 mM Tris-HCI (pH 6.5) containing 0.5% SDS, which was then boiled, and protein was extracted with an electroelution apparatus. After the elution, the protein was digested with 200 ng of trypsin (Sigma, St. Louis, Mo), dissolved in 50 mM Tris-HCI (pH 8.0) at 37°C for 11 hours.

The digestion product was applied to a reverse phase high performance liquid chromatography (Chemcosorb 3 ODS-H, Osaka Japan, 2.1×75 mm), and eluted under an acidic condition (0.1% TFA) using 0 - 60% acetonitrile gradient. An elution profile is shown in Fig. 7. The proteins of 60 kDa and 73 kDa show similar elution profiles and therefore it is concluded that both the proteins comprise basically same polypeptide, though there is possibility that they are partially enzymatically digested.

Example 5. Determination of partial amino acid sequences

To determine the amino acid sequences, the peptide fragments obtained in Example 2 from purified GnT-V were subjected to a Gas-phase sequencer (Applied Biosystem Inc. Foster City, CA), and the following sequences were obtained.

- (1) Thr-Pro-Trp-Gly-Lys
- (2) Asn-Ile-Pro-Ser-Tyr-Val
- (3) Val-Leu-Asp-Ser-Phe-Gly-Thr-Glu-Pro-Glu-Phe-Asn-His-Ala-Asn-Tyr-Ala
- (4) Asp-Leu-Gln-Phe-Leu-Leu
- (5) Asn-Thr-Asp-Phe-Phe-Ile-Gly

Example 6. Substrate Specificity

10

Substrate specificity was determined using the following compound as sugar acceptors according to the above-mentioned enzyme activity measuring method.

```
GlcNAcBl - 2Manal
                                             Manßl - 4GlcNAcßl - 4GlcNAc-PA
         GnGn-bi-PA
20
                      GlcNAcBl - 2Manal >
                      GlcNAcBl → 2Manαl
                                                        Fuc<sub>\alpha1</sub>
25
         GnGnF-bi-PA
                                             Manß1 - 4GlcNAcß1 - 4GlcNAc-PA
                      GlcNAcBl - 2Manol /
30
                      GlcNAcBl → 2Manαl
                                                        Fucal
                                             Manßl - 4GlcNAcßl - 4GlcNAc-PA
         GnGF-bi-PA
35
            Galßl - 4GlcNAcßl - 2Manal >
            Galß1 - 4GlcNAcß1 - 2Mancl
                                                        Fucal
40
                                             Manßl - 4GlcNAcßl - 4GlcNAc-PA
         GGnF-bi-PA
                      GlcNAcB1 - 2Manol >
45
                       GlcNAcBl - 2Manal
                                  GlcNAB1 - 4 ManB1 - 4GlcNAcB1 - 4GlcNAc-PA
          Gn(Gn)Gn-bi-PA
                       GlcNAcB1 - 2Mano1 /
50
                      GlcNAcBl - 2Mancl
                                                        Fuc@1
                               GlcNAcBl - 4 ManBl - 4GlcNAcBl - 4GlcNAc-PA
         Gn(Gn)GnF-bi-PA
55
                      GlcNAcBl - 2Manal >
```

```
Galßl - 4GlcNAcßl - 2Manol
                                                        Manßl - 4GlcNAcßl - 4GlcNA
              GG-bi-PA
5
                  Galß1 - 4GlcNAcß1 - 2Man@1 /
                                       Manc1 (
          MM-PA
                                                   Manßl - 4GlcNAcßl - 4GlcNAc-PA
10
                                                 3
                                       Mancl >
                          GlcNAcBl → 2Manαl
15
                                                     Manßl - 4GlcNAcBl - 4GlcNAc-PA
            GnM-PA
                                         Manol /
20
                        GlcNAcBl - 2Manal
                                                   Manßl - 4GlcNAcßl - 4GlcNAc-PA
          GnGnGn-tri-PA
25
                        GlcNAcB1 - 2Mano1 /
                        GlcNAcB1 /
     Lacto-N-triaose-PA
                           GlcNAc\beta1 \rightarrow 3Gal\beta1 \rightarrow 4Glc-PA
30
     Lacto-N-neotetraose-PA
                                Gal\beta 1 \rightarrow 4GlcNAc\beta 1 \rightarrow 3Gal\beta 1 \rightarrow 4Glc-PA
                          GlcNAcB1 (
35
                          GlcNAcBl - 2Manal
                                                     Manßl - 4GlcNAcßl - 4GlcNAc-PA
           GnGnGn-tri'-PA
                                                   3
                          GlcNAcB1 - 2Mano1 /
40
```

GnGnF-, GnGF-, Gn(Gn)GnF-, Gn(Gn)Gn-, GG-, GnGn-, MM- and GnM- were isolated from the bovine IgG treated with anhydrous hydrazine and then labeled with a fluorescence label according to Hase et al. method (Hase, S., Ibuki, T., and Ikehara, T., J. Biochem. 95, 197-203 (1984). The purified GnT-V was diluted with PBS buffer to a final concentration of 0.1 mg protein/ml, and then reacted with each fluorescence-labeled sugar acceptor. A result is shown in Table 2.

50

45

Table 2

	resent Enzyme to Various Sugar eptors
Acceptor (70 μM)	Relative reaction rate
GnGn-bi-PA	100
GnGnF-bi-PA	78
GnGF-bi-PA	3
GGnF-bi-PA	0.2
Gn(Gn)Gn-bi-PA	0
Gn(Gn)GnF-bi-PA	0
GG-bi-PA	0
MM-PA	0
GnM-PA	66
GnGnGn-tri-PA	125
Lacto-N-triaose-PA	0
Lacto-N-neotetraose-PA	0

It was found that the present enzyme reacts with all of GnGnF-bi-PA, GnM-PA and GnGnGn-tri-PA.

30 Example 7. Optimum pH

5

10

15

20

25

35

40

55

Assay mixtures containing 0.2M GlcNAc, 40 mM EDTA, 1% Triton X-100, and 40 mM UDP-GlcNAc in 0.25M potassium phosphate buffer of pH 6.0, 6.25, 6.5 or 7.0. To 25 μ l of the assay mixture were added 15 μ l of a test sample and 10 μ l of a substrate (GnGn-bi-PA), and the mixture was incubated at 37°C for 4 hours. A result is shown in Fig. 8.

Example 8. Isolation and identification of cDNA for GnT-V and Construction of expression vector

Oligomer S18 shown in SEQ ID No: 6 was synthesized on the basis of the amino acid sequence shown in SEQ ID No: 3 obtained in Example 5, and oligomer A21 shown in SEQ ID No: 7 was synthesized on the basis of the amino acid sequence shown in SEQ ID No: 5.

Double-stranded cDNA was synthesized from RNA having poly A prepared from QG cells using a cDNA synthesis kit (Pharmacia). Next, PCR was carried out using said cDNA as a templete, and the oligomers S18 and A21 as primers, and using Ampli-Taq DNA polymerase (Takara). As a result, a DNA fragment of about 500 base pairs (bp) which is a fragment of GnT-V cDNA.

Next, further cDNA cloning was carried out using the cDNA thus obtained as a probe. Namely, this cDNA was used as a template and labeled with α 32P-CTP using a random primer labeling kit (Amersham). The probe thus obtained was used to screen a human fetal liver cDNA library (Clone Tech?) according to a conventional procedure. Among the clones thus obtained, the longest clone was excised with EcoRI, and subcloned into pBluescript II ks(+) (Strate gene). Since the insert contains an EcoRI site, two fragments were obtained. Each of the two fragments was equenced, and B fragment of about 800 bp, and F fragment of about 1200 bp were obtained.

The sequences of the DNA fragments thus obtained were determined by Sequenase (U SB), and a result shown in SEQ ID NO: 8 was obtained. It was confirmed that this DNA fragment contains all the nucleotide sequences encoding five amino acid sequences obtained in Example 5.

Note, the cDNA fragment for GnT-V thus obtained does not reach to the stop codon at the 3'-terminus, and therefore 3'-terminal nucleotide sequence has not yet determined, but it is easy to determine the 3'-terminal nucleotide sequence has not yet determined, but it is easy to determine the 3'-terminal nucleotide sequence has not yet determined, but it is easy to determine the 3'-terminus.

minal nucleotide sequence for a person with ordinary skill in the art.

Next, to express the GnT-V cDNA fragment in animal cells, the cDNA fragment was inserted into an expression vector. Namely, an expression vector pSVK3 (Pharmacia) was digested with EcoRI and Small so that the above-mentioned F fragment was excised at the EcoRI site and the Small site inside of the insert, and inserted into an expression vector (see, Fig. 9).

Next, the vector incorporating the F fragment was cleaved with EcoRI, and treated with CIP (calf intestinal phosphatase) to prevent self-ligation. Next, the B fragment excised at EcoRI sites was inserted into the above-treated expression vector to construct an expression vector containing both the F fragment and B fragment.

Example 9. Expression of cloned GnT-V cDNA and enzyme activity of the expressed protein

The expression vector constructed in Example 8 was used to express the GnT-V cDNA fragment in animal cells and GnT-V activity of the expressed protein was tested.

Expression vector containing GnT-V cDNA fragment was transfected to COS-1 cells, animal cells for expression, by electroporation. Namely, about 5×10^6 CO.S-1 cells previously prepared were suspended in HEPES buffer (50 mM Hepes, 137 mM NaCl, 5 mM KCl, 0.7 mM NaHPO $_3$, 6 mM dextrose, pH 7.05), 60 μ g of the above-mentioned plasmid was added thereon, and 800 μ l of the suspension was subjected to electroporation in an electroporator (Bio-Rad) at 250V, 960 mF. Next, all the suspensions of COS-1 cells electroporated with GnT-V gene was plated in a peptri dish having the diameter of 6 cm, and cultured at 37°C in 5% CO $_2$ for 48 hours. The cultured cells were collected with a rubber-coated policeman bar, and suspended in 50 μ l of PBS buffer, and the cells were disrupted with a sonicator. Next, the disruptant was centrifuged to collect a supernatant, and 15 μ l of the supernatant was used to assay enzyme activity. A result is shown in Fig. 10.

From the result, it was confirmed that the cloned GnT-V cDNA fragment contain a minimum length necessary for expression of desired enzyme activity.

According to the present disclosure, UDP-N-acetylglucosamine: α -6-D-mannoside, β 1,6-N-acetylglucosaminyl transferase was isolated and purified from a culture supernatant of QG cells derived from human lung cancer cells, cultured in a protein-free medium, and properties and partial amino acid structure thereof were determined. Moreover, the present inventors clarified substrate specificity to various sugar acceptors, using the purified enzyme. The sugar transfer enzyme having such specificity is an important enzyme responsible for control of sugar chain biosynthesis path way. Moreover, it is now being clarified that the present enzyme participates to modification of sugar chains accompanying malignant alteration of cells.

Considering the above, not only the present enzyme is useful as a maker for malignancy of cells, but also by establishing a screening system for specific inhibitors against the present enzyme, it becomes possible to design cancer-metastasis inhibitors. In addition, since $\beta(1,6)$ branch structure can be introduced into various sugar acceptors exemplified using the present invention, oligosaccharides having $\beta(1,6)$ branch structure can be industrially produced. Moreover, from an aspect of sugar chain technology, homogeneous formation of sugar chains in the production of desired substance by genetic engineering is possible by using a large amount of the present enzyme.

40

10

25

45

50

SEQUENCE LISTING

5	(1) GENERAL INFORMATION:
10	 (i) APPLICANT: (A) NAME: Suntory Limited (B) STREET: 1-40, Dojimahama 2-chome, Kita-ku (C) CITY: Osaka-shi (D) STATE: Osaka
15	(E) COUNTRY: JAPAN (F) POSTAL CODE (ZIP):530
20	 (A) NAME: Taniguchi, Naoyuki (B) STREET: 201, 2-19-32 Uenohigashi, Toyonaka-shi (C) CITY: Osaka (E) COUNTRY: JAPAN (F) POSTAL CODE (ZIP): none
25	(ii) TITLE OF INVENTION: N-acetylglucosaminyl transferase, gene coding therefor, corresponding vectors and transformed hosts, processes for production thereof
30	(iii) NUMBER OF SEQUENCES: 8
35	 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: WordPerfect 5.1
40	(V) CURRENT APPLICATION DATA: APPLICATION NUMBER: EP 93306718.3
45	(vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: JP 4-245950 (B) FILING DATE: 24-AUG-1992
50	(vi) PRIOR APPLICATION DATA:(A) APPLICATION NUMBER: JP 5-237118(B) FILING DATE: 06-AUG-1993

	(2) INFORMATION FOR SEQ ID NO: 1:
5	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 5 amino acids(B) TYPE: Amino acid(D) TOPOLOGY: Linear
10	(ii) MOLECULE TYPE: Peptide
15	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Thr Pro Trp Gly Lys 5
20	(2) INFORMATION FOR SEQ ID NO: 2:
25	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: Amino acid(D) TOPOLOGY: Linear
30	<pre>(ii) MOLECULE TYPE: Peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:</pre>
35	Asn Ile Pro Ser Tyr Val
	(2) INFORMATION FOR SEQ ID NO: 3:
40	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17 amino acids(B) TYPE: Amino acid(D) TOPOLOGY: Linear
45	(ii) MOLECULE TYPE: Peptide
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
50	Val Leu Asp Ser Phe Gly Thr Glu Pro Glu Phe Asn His 5 10 Ala Asn Tyr Ala
	15
55	

	(2) INFORMATION FOR SEQ ID NO: 4:	
5	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: Amino acid(D) TOPOLOGY: Linear	
10	(ii) MOLECULE TYPE: Peptide	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:	
15	Asp Leu Gln Phe Leu Leu 5	
20	(2) INFORMATION FOR SEQ ID NO: 5:	
	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 7 amino acids(B) TYPE: Amino acid	
25	(D) TOPOLOGY: Linear	
	(ii) MOLECULE TYPE: Peptide	
30	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:	
35	Asn Thr Asp Phe Phe Ile Gly 5	
	(2) INFORMATION FOR SEQ ID NO: 6:	
40	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: Nucleic acid	
45	(C) STRANDEDNESS: Single (D) TOPOLOGY: Linear	
45	(ii) MOLECULE TYPE: Synthetic DNA	
50	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:	
	GGAATTC TTY AAY CAY GCN AAY TAY GC Phe Asn His Ala Asn Tyr Ala	27
55	5	

	(2) INFORMATION FOR SEQ ID NO: 7:	
5	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24 base pairs(B) TYPE: Nucleic acid(C) STRANDEDNESS: Single	
10	(D) TOPOLOGY: Linear	
	(ii) MOLECULE TYPE: Synthetic DNA (iv) ANTI-SENSE: Yes	
15	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:	
	TTR TGN CTR AAR AAR TACTTAAGG 24	
	Asn Thr Asp Phe Phe	
20	5	
	(2) INFORMATION FOR SEQ ID NO: 8:	
25	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 2095 base pairs	
	(B) TYPE: Nucleic acid	
	(C) STRANDEDNESS: Double	
30	(D) TOPOLOGY: Linear	
	(ii) MOLECULE TYPE: CDNA	
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:	
	CCGGCTGAAG CATCAGAATG GAAGTGAGGA AAGGCAACCA GCTGACACAG GAGCCAGAGT	60
	GAGACCAGCA GACTCTCACA CTCAACCTAC ACCATGAATT TGTGTCTATC TTCTACGCGT	120
40	TAAGAGCCAA GGACAGGTGA AGTTGCCAGA GAGCA ATG GCT CTC TTC ACT CCG	173
	Met Ala Leu Phe Thr Pro	
	TGG AAG TTG TCC TCT CAG AAG CTG GGC TTT TTC CTG GTG ACT TTT GGC	221
	Trp Lys Leu Ser Ser Gln Lys Leu Gly Phe Phe Leu Val Thr Phe Gly	221
45	10 15 20	
	TTC ATT TGG GGT ATG ATG CTT CTG CAC TTT ACC ATC CAG CAG CGA ACT	269
	Phe Ile Trp Gly Met Met Leu Leu His Phe Thr Ile Gln Gln Arg Thr	
50	25 30 35	
	CAG CCT GAA AGC AGC TCC ATG CTG CGC GAG CAG ATC CTG GAC CTC AGC	317
	Gln Pro Glu Ser Ser Met Leu Arg Glu Gln Ile Leu Asp Leu Ser	
	40 45 50	

	AAA	AGG	TAC	ATC	AAG	GCA	CTG	GCA	GAA	GAA	AAC	AGG	AAT	GTG	GTG	GAT	365
												Arg					
5	55	_	•		•	60					65					70	
	GGG	CCA	TAC	GCT	GGA	GTC	ATG	ACA	GCT	TAT	GAT	CTG	AAG	AAA	ACC	CTT	413
												Leu					
					75					80					85		
10	GCT	GTG	TTA	TTA	GAT	AAC	ATT	TTG	CAG	CGC	ATT	GGC	AAG	TTG	GAG	TCG	461
	Ala	Val	Leu	Leu	Asp	Asn	Ile	Leu	Gln	Arg	Ile	Gly	Lys	Leu	Glu	Ser	
				90					95					100			
	AAG	GTG	GAC	AAT	CTT	GTT	GTC	AAT	GGC	ACC	GGA	ACA	AAC	TCA	ACC	AAC	50 9
15	Lys	Val	Asp	Asn	Leu	Val	Val	Asn	Gly	Thr	Gly	Thr	Asn	Ser	Thr	Asn	
			105					110					115				
	TCC	ACT	ACA	GCT	GTT	CCC	AGC	TTG	GTT	GCA	CTT	GAG	AAA	ATT	AAT	GTG	557
	Ser	Thr	Thr	Ala	Val	Pro	Ser	Leu	Val	Ala	Leu	Glu	Lys	Ile	Asn	Val	
20		120					125					130					
												GTA					605
	Ala	Asp	Ile	Ile	Asn	_	Ala	Gln	Glu	Lys	_	Val	Leu	Pro	Pro		
	135					140					145					150	
25												TGG _					653
	Asp	Gly	Tyr	Pro		Cys	Glu	Gly	Lys		Lys	Trp	Met	Lys		Met	
					155					160					165		501
												GTG					701
30	Trp	Arg	Ser		Pro	Cys	туг	Ala		Tyr	GIY	Val	Asp		ser	Thr	
	TCC	TOT	TT*	170	አጥጥ	ሞክሮ	CTC) CT	175	CTT	CAA	AAT	тсс	180 TGT	CCT	САТ	749
												Asn					143
	Суѕ	Ser	185	File	116	TYL	Deu	190	Giu	Vai	GIU	nan	195	Cys	110		
35	ፈ ጥፒ	ССТ		AGA	GCA	ДДД	таа		TAC	GAA	GAA	GCT		CAT	ААТ	TCA	797
												Ala					
	204	200		9		-1-	205		-1-			210					
	TTG		GAA	ATT	CGT	ACA		TTT	AAT	ATT	CTC	TAC	AGT	ATG	ATG	AAA	845
40												Tyr					
	215				_	220	-				225	-				230	
	AAG	CAT	GAA	GAA	TTC	CGG	TGG	ATG	AGA	CTA	CGG	ATC	CGG	CGA	ATG	GCT	893
	Lys	His	Glu	Glu	Phe	Arg	Trp	Met	Arg	Leu	Arg	Ile	Arg	Arg	Met	Ala	
45					235					240					245		
	GAC	GCA	TGG	ATC	CAA	GCA	ATC	AAG	TCC	CTG	GCA	GAA	AAG	CAG	AAC	CTT	941
	Asp	Ala	Trp	Ile	Gln	Ala	Ile	Lys	Ser	Leu	Ala	Glu	Lys	Gln	Asn	Leu	
				250					255					260			
50	GAA	AAG	AGA	AAG	CGG	AAG	AAA	GTC	CTC	GTT	CAC	CTG	GGA	CTC	CTG	ACC	989
	Glu	Lys	Arg	Lys	Arg	Lys	Lys	Val	Leu	Val	His	Leu	Gly	Leu	Leu	Thr	
			265					270					275				
	AAG	GAA	TCT	GGA	TTT	AAG	ATT	GCA	GAG	ACA	GCT	TTC	AGT	GGT	GGC	CCT	1037
55	Lys	Glu	Ser	Gly	Phe	Lys	Ile	Ala	Glu	Thr	Ala	Phe	Ser	Gly	Gly	Pro	
		280					285					290					

	CTT	CGT	GAA	тта	GTT	CAA	TGG	AGT	GAT	TTA	ATT	ACA	TCT	CTG	TAC	TTA	1085
					Val												
	295	Gry	014	200	*41	300					305				-	310	
5		GGC	САТ	GAC	ATT		ATT	TCA	GCT	TCA	CTG	GCT	GAG	CTC	AAG	GAA	1133
					Ile												
	Deu	011			315	5				320					325		
	ΔͲC	атс	AAG	AAG	GTT	GTA	GGA	AAC	CGA	TCT	GGC	TGC	CCA	ACT	GTA	GGA	1181
10					Val												
	110	1100	ביים	330			1		335			•		340		-	
	GAC	AGA	АТТ	-	GAG	CTC	ATT	TAC	ATT	GAT	ATT	GTA	GGA	CTT	GCT	CAA	1229
					Glu												
15	*p	••••	345		-			350		•			355				
	ттс	AAG		ACT	CTT	GGA	CCA	TCC	TGG	GTT	CAT	TAC	CAG	TGC	ATG	CTC	1277
					Leu												
		360	- 4			•	365		_			375					
20	CGA		CTT	GAT	TCA	TTT	GGT	ACT	GAA	ccc	GAA	TTT	AAT	CAT	GCA	AAT	1325
					Ser												
	380			_		385					390					395	
	TAT	GCC	CAA	TCG	AAA	GGC	CAC	AAG	ACC	CCT	TGG	GGA	AAA	TGG	AAT	CTG	1373
25	Tyr	Ala	Gln	Ser	Lys	Gly	His	Lys	Thr	Pro	Trp	Gly	Lys	Trp	Asn	Leu	
	-				400					405					410		
	AAC	CCT	CAG	CAG	TTT	TAT	ACC	ATG	TTC	CCT	CAT	ACC	CCA	GAC	AAC	AGC	1421
	Asn	Pro	Gln	Gln	Phe	Tyr	Thr	Met	Phe	Pro	His	Thr	Pro	Asp	Asn	Ser	
30				415					420					425			
00	TTT	CTG	GGG	TTT	GTG	GTT	GAG	CAG	CAC	CTG	AAC	TCC	AGT	GAT	ATC	CAC	1469
	Phe	Leu	Gly	Phe	Val	Val	Glu	Gln	His	Leu	Asn	Ser	Ser	Asp	Ile	His	
			430					435					440				
35	CAC	ATT	AAT	GAA	ATC	AAA	AGG	CAG	AAC	CAG	TCC	CTT	GTG	TAT	GGC	AAA	1517
55	His	Ile	Asn	Glu	Ile	Lys	Arg	Gln	Asn	Gln	Ser	Leu	Val	Tyr	Gly	Lys	
		445					450					455					
	GTG	GAT	AGC	TTC	TGG	AAG	TAA	AAG	AAG	ATC	TAC	TTG	GAC	ATT	ATT	CAC	1565
40	Val	Asp	Ser	Phe	Trp	Lys	Asn	Lys	Lys	Ile	Tyr	Leu	Asp	Ile	Ile	His	
40	460					465					470					475	
	ACA	TAC	ATG	GAA	GTG	CAT	GCA	ACT	GTT	TAT	GGC	TCC	AGC	ACA	AAG	AAT	1613
	Thr	Tyr	Met	Glu	Val	His	Ala	Thr	Val	Tyr	Gly	Ser	ser	Thr	Lys	Asn	
45					480					485					490		
45					GTG												1661
	Ile	Pro	Ser	Tyr	Val	Lys	Asn	His	Gly	Ile	Leu	Ser	Gly	Arg	Asp	Leu	
				495					500					505			
	CAG	TTC	CTT	CTT	CGA	GAA	ACC	AAG	TTG	TTT	GTT	GGA	CTT	GGG	TTC	CCT	1709
50	Gln	Phe	Leu	Leu	Arg	Glu	Thr	Lys	Leu	Phe	Val	Gly	Leu	Gly	Phe	Pro	
			510					515					520				
					GCT												1757
	Tyr	Glu	Gly	Pro	Ala	Pro	Leu	Glu	Ala	Ile	Ala		Gly	Cys	Ala	Phe	
55		525					530					535					

	CTG	AAT	ccc	AAG	TTC	AAC	CCA	ccc	AAA	AGC	AGC	AAA	AAC	ACA	GAC	TTT	1805
	Leu	Asn	Pro	Lys	Phe	Asn	Pro	Pro	Lys	Ser	Ser	Lys	Asn	Thr	Asp	Phe	
	540					545					550					555	
5	TTC	ATT	GGC	AAG	CCA	ACT	CTG	AGA	GAG	CTG	ACA	TCC	CAG	CAT	CCT	TAC	1853
	Phe	Ile	Gly	Lys	Pro	Thr	Leu	Arg	Glu	Leu	Thr	Ser	Gln	His	Pro	Tyr	
					560					565					570		
	GCT	GAA	GTT	TTC	ATC	GGG	CGG	CCA	CAT	GTG	TGG	ACT	GTT	GAC	CTC	AAC	1901
10	Ala	Glu	Val	Phe	Ile	Gly	Arg	Pro	His	Val	Trp	Thr	Val	Asp	Leu	Asn	
				575					580					58 5			
	AAT	CAG	GAG	GAA	GTA	GAG	GAT	GCA	GTG	AAA	GCA	ATT	TTA	AAT	CAG	AAG	1949
	Asn	Gln	Glu	Glu	Val	Glu	Asp	Ala	Val	Lys	Ala	Ile	Leu	Asn	Gln	ГÅа	
15			590					595					600				
	ATT	GAG	CCA	TAC	ATG	CCA	TAT	GAA	TTT	ACG	TGC	GAG	GGG	ATG	CTA	CAG	1997
	Ile	Glu	Pro	Tyr	Met	Pro	Tyr	Glu	Phe	Thr	Cys	Glu	Gly	Met	Leu	Gln	
		605					610					615					
20	AGA	ATC	AAT	GCT	TTC	ATT	GAA	AAA	CAG	GAC	TTC	TGC	CAT	GGG	CAA	GTG	2045
	Arg	Ile	Asn	Ala	Phe	Ile	Glu	Lys	Gln	Asp	Phe	Cys	His	Gly	Gln	Val	
	620					625					630					635	
	ATG	TGG	CCA	CCC	CTC	AGC	GCC	CTA	CAG	GTC	AAG	CTT	GCT	GAG	CCC	GGG	2093
25	Met	Trp	Pro	Pro	Leu	Ser	Ala	Leu	Gln	Val	Lys	Leu	Ala	Glu	Pro	Gly	
					640					645					650		
	CC																2095

30

35

40


45


Claims


- 1. A β1,6-N-acetylglucosaminyl transferase having the following properties:
 - (1) Action: it transfers N-acetylglucosamine from UDP-N-acetylglucosamine to α -6-D-mannoside;
 - (2) Substrate specificity: it shows a reactivity of about 79% for GnGnF-bi-PA, about 125% for GnGnGntri-PA and about 66% for GnM-PA, when taking a reactivity for GnGn-bi-PA as 100%;
 - (3) Optimum pH: 6.2 to 6.3;
 - (4) Inhibition, Activation and Stability: Mn²⁺ is not necessary for expression of activity, and the activity is not inhibited in the presence of 20 mM EDTA;
 - (5) Molecular weight: about 73,000 as determined by SDS-PAGE in the absence of reducing agent; and about 73,000 and about 60,000 as determined in the presence of a reducing agent;
 - (6) Km value: 133 μ M and 3.5 mM for acceptor GnGn-bi-PA and donor UDP-GlcNAc, respectively; and (7) It includes the following peptide fragments:
 - (1) Thr-Pro-Trp-Gly-Lys
 - (2) Asn-Ile-Pro-Ser-Tyr-Val
 - $\hbox{(3) Val-Leu-Asp-Ser-Phe-Gly-Thr-Glu-Pro-Glu-Phe-Asn-His-Ala-Asn-Tyr-Ala}\\$
 - (4) Asp-Leu-Gln-Phe-Leu-Leu
 - (5) Asn-Thr-Asp-Phe-Phe-Ile-Gly.


- A β1,6-N-acetylglucosaminyl transferase consisting essentially of an amino acid sequence shown in SEQ ID No: 8.
- A β1,6-N-acetylglucosaminyl transferase consisting essentially of an amino acid sequence having one or more amino acid modifications in the amino acid sequence shown in SEQ ID No: 8.
 - **4.** A β1,6-N-acetylglucosaminyl transferase according to claim 3 wherein the amino acid modification is addition, deletion, replacement with other amino acids, or a combination thereof.


	5.	DNA coding for β1,6-N-acetylglucosaminyl transferase according to any one of claims 1 to 4.
	6.	DNA according to claim 5 consisting essentially of a nucleotide sequence as shown in SEQ ID No. 8.
5	7.	An expression vector comprising DNA according to claim 5 or claim 6.
	8.	A host transformed with an expression vector according to claim 7.
10	9.	A process for production of a β 1,6-N-acetylglucosaminyl transferase according to any one of claims 1 to 4, comprising the steps of: culturing or raising a host transformed with a DNA coding for said enzyme, and recovering the enzyme from the culture or the raised host.
15		
20		
25		
30		
35		
40		
45		
50		
55		














ACTIVITY





27

Fig. 8



рН_	ACTIVITY
6.0	12.7 (nmol/hr/mg)
6.25	15.3
6.5	10.8
7.0	7.8




Fig. 10

